Author: Fiona Craig

New Health Positioned for Launch of Oral GLP-1 Therapy

MedPal AI (LSE:MPAL) believes its private weight-management platform, New Health, is well placed to benefit from the UK launch of the first oral GLP-1 receptor agonist approved for weight loss following an earlier-than-expected authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA).

The treatment is currently available only through private prescriptions, creating an opportunity for providers capable of delivering accessible and scalable weight-management services. MedPal AI expects growing interest from patients seeking an alternative to injectable therapies as New Health expands its national rollout.

Technology Platform Designed to Support Growing Demand

The company’s offering combines AI-powered patient triage, clinician supervision and automated pharmacy fulfilment to streamline the treatment pathway from consultation to prescription delivery.

Through this integrated model, MedPal AI aims to provide a convenient route for patients seeking weight-loss therapies while leveraging its digital healthcare infrastructure to manage increasing demand efficiently.

Management believes the availability of an oral treatment option could broaden the appeal of GLP-1 therapies among individuals who may be reluctant to use injectable medications.

U.S. Adoption Highlights Market Potential

The board has pointed to the strong commercial performance of oral semaglutide in the United States as an indicator of potential demand in the UK market.

According to the company, more than three million prescriptions have been issued in the U.S. within just over five months of launch, with many users being first-time GLP-1 patients. MedPal AI believes this trend demonstrates how tablet-based therapies can expand the addressable market beyond traditional injectable treatment users.

Private Market Opportunity Remains Significant

With NHS access not currently available and a formal evaluation by the National Institute for Health and Care Excellence (NICE) still pending, the company sees a substantial opportunity within the private healthcare sector.

Management believes this environment could strengthen New Health’s competitive position and support continued growth across MedPal AI’s broader digital healthcare and pharmacy operations as demand for weight-management treatments continues to increase.

More About MedPal AI

MedPal AI Plc is a UK-based digital health and pharmacy technology company developing the MedPal Health OS, an AI-driven healthcare platform that integrates wellness tools, clinician-led services and prescription fulfilment.

Through its subsidiary, MedPal Limited, the group operates a 24-hour AI-enabled pharmacy distribution centre that provides nationwide NHS and private prescription services. The business combines artificial intelligence, robotic dispensing technology and rapid delivery capabilities to create a fully integrated digital healthcare ecosystem.

Refinancing Strengthens Financial Flexibility

Severfield plc (LSE:SFR) has completed the refinancing of its principal borrowing facilities through a new three-year banking agreement with its existing syndicate of lenders.

The package includes the renewal of the group’s £60 million revolving credit facility, the continuation of its £7.6 million term loan through to December 2027 and the introduction of an accordion facility that could provide access to an additional £30 million if required.

Improved Terms Extend Debt Maturities

The unsecured refinancing arrangement extends the maturity profile of Severfield’s debt facilities to June 2029, with options available to further extend the agreement.

Management said the revised package has been secured on improved commercial terms, providing greater financial flexibility and reinforcing the company’s liquidity position as it continues to pursue operational and strategic objectives across its UK and European businesses.

The agreement also reflects continued support from the company’s lending partners and confidence in Severfield’s financial strength and market position.

Enhanced Liquidity Supports Growth Opportunities

The new facilities are designed to support day-to-day operations while providing additional capacity for investment and future growth initiatives.

With access to the expanded funding package, Severfield believes it is well positioned to pursue opportunities across its core markets while maintaining a disciplined approach to capital allocation and balance sheet management.

The additional flexibility could also help the group navigate changing market conditions while supporting long-term strategic development.

Market Challenges Continue to Influence Outlook

Despite the refinancing milestone, Severfield continues to operate in a challenging trading environment characterised by pressure on revenues and profitability.

While recent corporate developments and certain technical indicators have offered more positive signals, valuation metrics remain under pressure and liquidity considerations continue to be monitored by investors.

The company’s dividend yield remains a supportive factor, while the alignment of management incentives with shareholder interests is viewed as a positive element within the broader investment case.

More About Severfield

Severfield plc is one of the UK’s leading structural steel specialists, providing design, fabrication and construction services for steel superstructures. The group has annual production capacity of approximately 150,000 tonnes across six manufacturing facilities and employs around 1,800 people.

Its projects span a wide range of sectors, including industrial and logistics, commercial offices, data centres, retail, healthcare, education, transport, energy, nuclear and leisure developments. Severfield also maintains a presence in India through its joint venture with JSW Steel, supporting growth in one of the world’s largest infrastructure markets.

Landmark Year Marks Transition to AI-Focused Business

Pri0r1ty Intelligence Group PLC (LSE:PR1) has reported its first full-year results since completing its transition from a listed cash shell into an artificial intelligence-driven technology and services group and restoring trading of its shares on AIM.

During the period, the company completed the reverse acquisition of Pri0r1ty AI, acquired sports marketing specialist Halfspace and raised £1.8 million to support growth initiatives. The group also established a portfolio of businesses focused on delivering solutions across targeted sectors including sport, music, entertainment and lifestyle.

Revenue Growth Established Following Strategic Restructuring

For the year ended 30 September 2025, Pri0r1ty generated revenue of £174,174 and recorded gross profit of £133,511 as it began building its commercial operations following the transformation.

The company reported a pre-tax loss of £10.3 million, although the result was significantly influenced by a £7.0 million non-cash accounting charge associated with the reverse takeover process rather than underlying trading performance.

Management noted that the figures reflect a business still in the early stages of scaling its operations following a major corporate restructuring.

Client Wins and Product Expansion Support Growth Strategy

The group continued to build momentum throughout the year, securing contracts and relationships with organisations including Aston Villa FC and World Aquatics.

Pri0r1ty also expanded its product offering through the launch of Fan Sonar and Advisor 2.0, two AI-powered solutions designed to enhance customer engagement and business decision-making.

Alongside product development, the company strengthened its leadership team as it seeks to accelerate growth across its SaaS and data-driven marketing activities.

Early Signs of Commercial Momentum

Eight months into the current financial year, the group reported contracted revenue exceeding £0.4 million, providing evidence of growing market adoption of its services.

Management believes this progress demonstrates early traction for its strategy of delivering AI-powered software and marketing solutions to small and medium-sized enterprises on a global scale.

The company continues to focus on expanding recurring SaaS revenues while leveraging its sector expertise across sports, entertainment and lifestyle markets.

More About Pri0r1ty Intelligence Group

Pri0r1ty Intelligence Group PLC is a data, artificial intelligence and marketing services business focused on helping small and medium-sized enterprises accelerate growth. Through its Halfspace, Pri0r1ty and Metr1c divisions, the company provides AI-driven software solutions, data-led marketing services and commercial partnership strategies across the sports, music, entertainment and lifestyle sectors. Its long-term strategy centres on scaling AI-enabled SaaS products while building a diversified portfolio of specialist digital businesses.

Canadian Defence Department Selects Auxilium Suite

Pennant International (LSE:PEN) has secured a multiyear Integrated Product Support services contract through its Canadian subsidiary to provide and optimise its Auxilium software suite for maritime programmes within Canada’s Department of National Defence (DND).

The agreement strengthens Pennant’s long-standing relationship with the DND and further expands the deployment of its Auxilium platform, which combines the GenS, Analyzer and R4i applications to support the management of complex equipment data and regulatory compliance requirements.

Contract Could Deliver Up to C$35 Million in Revenue

The framework agreement has an initial term of five years and includes extension options that could take the total duration to 11 years.

Based on historic usage levels, Pennant estimates the contract will generate approximately C$15 million during the initial period and could be worth as much as C$35 million over its full lifespan. The award provides additional visibility over future revenues and supports the continued expansion of the group’s software and services operations.

Software Strategy Focused on Recurring Revenue Growth

Auxilium forms a central part of Pennant’s strategy to increase recurring revenues through software solutions used in highly regulated industries.

The platform helps customers manage technical documentation, maintenance information and product support requirements while ensuring compliance with industry standards. Demand for such solutions is being driven by rising defence spending and the increasing complexity of modern military and industrial platforms.

With operations across the UK, North America and Asia-Pacific, Pennant continues to target opportunities in sectors where long-term support, data management and compliance are critical.

Financial Challenges Continue to Weigh on Outlook

Despite the positive contract win, the company’s outlook remains affected by recent financial performance. Revenue declined during 2025, operating losses re-emerged and pressure on shareholder equity persisted.

Technical indicators also remain weak, with the share price trading below key moving averages and momentum measures such as the RSI signalling limited investor enthusiasm. Valuation metrics offer little support, as the company remains loss-making and does not currently provide a dividend yield.

More About Pennant International

Pennant International Group is a technology-focused provider of integrated support software, technical services and training solutions for organisations operating complex assets. The company serves customers across the aerospace, defence and rail sectors, as well as other safety-critical industries including shipping, nuclear energy and space. Pennant is increasingly focused on expanding higher-margin, recurring software and support revenues as part of its long-term growth strategy.

Term Loan Reaches Strongest Level Since 2021

THG PLC (LSE:THG) has announced that its €445 million Term Loan B, issued in March 2025, has traded above par value for the first time and reached its highest level since November 2021.

The milestone follows a succession of positive trading updates throughout 2025 and 2026 and marks the strongest performance recorded by any of the group’s term loan facilities in nearly five years.

Secondary Market Performance Outpaces Industry Benchmark

Since the beginning of 2026, the loan has appreciated by approximately 500 basis points, resulting in a reduction in yield of around 1.3%.

Over the same period, the facility has outperformed the European Leveraged Loan Index by roughly 400 basis points, highlighting growing investor appetite for THG’s debt and improving sentiment towards the company’s credit profile.

The performance reflects increasing confidence among lenders and institutional investors in the group’s financial outlook and strategic direction.

Stronger Credit Perception Could Improve Financing Options

The move above par value is a notable indicator of market confidence and may enhance THG’s future access to capital.

A stronger trading performance in the debt market can improve funding flexibility, potentially reducing borrowing costs and strengthening the company’s position should it seek refinancing or additional financing opportunities in the future.

Management views the performance as evidence of the positive reception received from investors following recent operational and trading progress.

Financial Recovery Continues Despite Ongoing Challenges

While market sentiment towards the company’s debt has improved, THG’s broader financial outlook remains constrained by ongoing profitability and cash flow challenges.

Although earnings improved during 2025, the group continues to report negative operating profitability, while both operating cash flow and free cash flow remain negative. Leverage levels also continue to be relatively elevated.

Technical indicators provide some support, with momentum measures remaining positive. Valuation metrics appear broadly moderate based on earnings multiples, although the absence of a dividend limits the stock’s appeal for income-focused investors.

More About THG

THG PLC is a global e-commerce and consumer brands group headquartered in Manchester. The company operates through its THG Beauty and THG Nutrition divisions, serving customers across international markets.

THG Beauty manages major online retail platforms including Lookfantastic, Dermstore and Cult Beauty, offering products from more than 1,000 third-party brands alongside its own portfolio. THG Nutrition is led by Myprotein, one of the world’s largest online sports nutrition brands, and provides a wide range of health, wellness and performance products through both direct-to-consumer and wholesale channels.

Regulatory Milestone Achieved in Rare Disease Programme

GSK (LSE:GSK) has been granted Orphan Drug Designation by both U.S. and European regulatory authorities for momelotinib as a potential treatment for VEXAS syndrome, a rare and life-threatening clonal myeloid disorder that currently has no approved therapies.

The condition is associated with significant morbidity and a high mortality rate within five years of diagnosis, creating a substantial unmet medical need for affected patients.

Momelotinib Could Address Multiple Disease Pathways

Momelotinib is already approved in several major markets for the treatment of specific myelofibrosis indications and works by targeting the JAK1, JAK2 and ACVR1 pathways.

The drug’s mechanism of action may provide benefits for patients with VEXAS syndrome by helping to manage inflammatory symptoms while also addressing anaemia, a common and debilitating feature of the disease. This positions the therapy as a potential treatment option for patients suffering from severe haemato-inflammatory disorders.

Designations Support Development and Regulatory Progress

The orphan designations are expected to facilitate the development and regulatory pathway for momelotinib as GSK continues to advance its Phase II/III ATLAS clinical trial.

The study is evaluating the safety and efficacy of the treatment in patients with VEXAS syndrome and will form a key part of the company’s future global regulatory submissions.

If successful, the programme could expand momelotinib’s commercial opportunity beyond myelofibrosis and establish a presence in a new rare disease indication, further strengthening GSK’s position within the haematology market.

Financial Strength Balances Development Opportunity

GSK’s outlook continues to be supported by strong underlying operating performance, including healthy profit margins and improving earnings trends. The company also benefits from a relatively attractive valuation, supported by a low price-to-earnings ratio and a dividend yield of approximately 3.47%.

These strengths are partially offset by weaker technical indicators, with the shares trading below key moving averages and showing a negative MACD reading. Investors also continue to monitor financial risks associated with leverage levels and fluctuations in free cash flow generation.

More About GSK

GSK is a global biopharmaceutical company focused on the research, development and commercialisation of innovative medicines and vaccines. The company operates across a broad range of therapeutic areas and is increasingly expanding its presence in haematology and inflammatory diseases while continuing to build on its established portfolio of specialty medicines and vaccines.

Production Growth Driven by Strong Harvest and Improved Extraction Rates

M.P. Evans (LSE:MPE) reported solid operational progress during the five months to 31 May 2026, with fresh fruit bunch production increasing 10% to 575,100 tonnes and crude palm oil (CPO) output rising 8% to 157,600 tonnes.

The improvement was supported by stronger extraction rates and the company’s continued focus on expanding production from its own-managed plantations, which typically deliver higher-quality yields than externally sourced crop.

Sustainability also remained a key focus, with approximately 82% of the group’s CPO production now certified as sustainable.

Pricing Remains Supportive as Costs Stay Under Control

The company said market conditions remained favourable, with both crude palm oil and palm kernel prices continuing to trade at healthy levels.

Despite broader inflationary pressures affecting agricultural inputs globally, M.P. Evans maintained broadly stable unit production costs, supporting profitability and operational efficiency across its plantation portfolio.

Management also noted that proposed changes to Indonesian export regulations are not expected to have a material impact on the business, as the group sells its palm oil into the domestic market rather than exporting CPO directly. To date, no significant effect on pricing has been observed.

Capital Returns Strengthened Through Buybacks and Dividend Growth

M.P. Evans highlighted continued progress at its recently acquired estates in East Kalimantan, where yields are improving as integration efforts advance.

Reflecting confidence in the business and its outlook, the company has resumed its share buyback programme with an initial £2.0 million allocation. It also plans to seek broader buyback authority from shareholders at its upcoming annual general meeting.

In addition, the board has proposed a record total dividend of 60p per share for 2025, reinforcing its commitment to a progressive capital-return strategy.

Strong Fundamentals Continue to Support Outlook

The group’s outlook remains underpinned by robust financial performance, characterised by strong profitability, solid cash generation and a debt-free balance sheet.

Valuation metrics also remain attractive, supported by a low price-to-earnings ratio and a healthy dividend yield. While technical indicators continue to point to a positive longer-term trend, elevated RSI and stochastic readings suggest momentum may be stretched in the near term, potentially limiting short-term upside.

More About M.P. Evans

M.P. Evans Group PLC is a UK-listed producer of sustainable palm oil with plantation and milling operations across Indonesia. The company focuses on producing higher-quality crude palm oil and palm kernels from its own-managed estates, supplying domestic Indonesian refiners rather than exporting directly. Through its emphasis on operational efficiency, sustainability and RSPO-certified production, the group has established itself as a significant participant in Indonesia’s palm oil sector.

Italian Solar Portfolio Positioned to Benefit from State Support

Zenith Energy (LSE:ZEN) is seeking to capitalise on Italy’s newly approved €23 billion renewable energy support programme through its solar development subsidiary, WESOLAR.

The company currently controls a solar portfolio with a total capacity of 188.5 MWp and is focusing on projects below 10 MWp in strategically selected areas to streamline permitting procedures and secure grid access more efficiently. Construction of WESOLAR’s first 7 MWp project cluster in the Puglia region is scheduled to begin in July 2026.

Long-Term Revenue Support Could Enhance Project Economics

The Italian initiative, which has received backing from the European Union, is designed to accelerate the deployment of renewable electricity generation across the country. The scheme will provide successful projects with 20-year two-way Contracts for Difference (CfDs), offering greater revenue certainty and reducing exposure to power price volatility.

The programme is expected to support the development of approximately 37.15 GW of new renewable energy capacity, including solar installations. Zenith believes its WESOLAR projects could qualify for the scheme, potentially improving project economics and strengthening the attractiveness of its development pipeline.

Financing and Asset Values Could Receive a Boost

Should WESOLAR secure access to the programme, Zenith expects the enhanced revenue visibility to improve financing opportunities for its projects and support higher asset valuations.

The company believes this could further strengthen its build-and-sell business model, increasing the appeal of its renewable assets to lenders, infrastructure investors and institutional buyers as Italy continues to expand its renewable energy capacity.

Financial and Technical Challenges Remain

Despite the growth opportunity presented by the Italian renewables market, Zenith’s outlook continues to be weighed down by financial pressures. The company has reported recurring negative operating and free cash flow, returned to significant losses in 2026 and has seen debt levels increase.

Technical indicators also remain weak, with a negative MACD reading and the share price trading below key moving averages, suggesting a bearish trend. Valuation metrics remain constrained by the company’s loss-making position, resulting in a negative price-to-earnings ratio and no dividend support.

More About Zenith Energy

Zenith Energy Ltd. is an independent energy company with producing, exploration and development assets across North Africa, the United States and Europe. Listed in London, Oslo and on Sweden’s Spotlight market, the company focuses on acquiring and developing proven energy assets capable of generating cash flow while pursuing low-risk exploration opportunities in established producing regions.

U.S. Patent Secures Protection for CIZ1B Testing Technology

Cizzle Biotechnology (LSE:CIZ) has been granted a significant U.S. patent covering its proprietary methods for detecting and measuring the CIZ1B lung cancer biomarker. The award extends the company’s intellectual property protection in a key market, complementing existing patent coverage across Europe and Canada.

The patent is expected to support the commercial activities of Cizzle Bio Inc, the company’s North American licensing partner, which is preparing to introduce the two-step ELISA-based lung cancer test across the United States and Caribbean region.

Expanded IP Coverage Supports Commercialisation Strategy

The latest patent strengthens Cizzle’s broader strategy of licensing its early-stage lung cancer diagnostic technology worldwide. Management believes the enhanced intellectual property position will help create additional opportunities for licensing agreements and future royalty streams.

Protection across North America and Europe is also expected to support discussions with clinical laboratories, healthcare providers and NHS-associated organisations as the company advances the commercial rollout of its blood-based cancer detection test.

Focus on Earlier Cancer Detection

Cizzle’s technology is designed to assist in the early identification of lung cancer through a simple blood test that measures the CIZ1B biomarker. The company aims to align the deployment of the test with wider healthcare initiatives focused on improving early diagnosis rates and patient outcomes.

A stronger patent portfolio is expected to play an important role in supporting adoption and partnership opportunities as the technology moves into additional markets.

Financial Challenges Continue Despite Technical Momentum

The company’s outlook remains constrained by its financial profile, which includes a lack of revenue generation, ongoing losses and continued cash consumption. Negative profitability and the absence of dividend support also weigh on valuation metrics.

However, technical indicators have remained favourable, reflecting a strong upward trend in the share price. Investors should note that momentum measures currently suggest overbought conditions, which may increase near-term volatility.

More About Cizzle Biotechnology Holdings

Cizzle Biotechnology Holdings PLC is a UK-based life sciences company focused on the development of diagnostic technologies for the early detection of cancer, with a particular emphasis on lung cancer. Its lead product is a non-invasive blood test designed to detect the CIZ1B biomarker. The company operates a global licensing model that includes royalty-based agreements and collaborations with healthcare providers and cancer treatment centres, leveraging its London Stock Exchange listing to support commercial growth.